Search
Close
Search
Advanced Search
Search Menu

Abstract

Drug delivery to brain tumors has been a controversial subject. Some believe the blood-brain barrier is not important, while others believe it is the major obstacle in treatment and have devised innovative approaches to circumvent it. These approaches can be divided into two categories: those that attempt to increase drug delivery of intravascularly administered drugs by manipulating either the drugs or capillary permeability, and those that attempt to increase drug delivery by local administration. Several strategies have been developed to increase the fraction of intravascular drug reaching the tumor, including intra-arterial administration, barrier disruption, new ways of packaging drugs, and, most recently, inhibiting drug efflux from tumor. When given intravascularly, all drugs have a common drawback: the body acts as a sink, and, even in the best situations, only a small fraction of administered drug actually reaches the tumor. A consequence is that systemic toxicity is usually the dose-limiting factor. When given locally, such as into the cerebrospinal fluid or directly into the tumor, 100% of an administered dose is delivered to the target site. However, local delivery is associated with variable and unpredictable spatial distribution and variation in drug concentration. The major dose-limiting factor of most local delivery methods will be neurotoxicity. The relative advantages and disadvantages of the different methods of circumventing the blood-brain barrier are presented in this review, and special attention is given to convection-enhanced delivery, which has particular promise for the local delivery of large therapeutic agents such as monoclonal antibodies, antisense oligonucleotides, or viral vectors.

References

Ali-Osman, F. (

1999
) Human glioma cultures and in vitro analysis of therapeutic response. In Berger, M.S., and Wilson, C.B. (Eds.),
The Gliomas
. Philadelphia: W.B. Saunders Co. pp.
134
-142.

Allen, T.M., and Moase, E.H. (

1996
) Therapeutic opportunities for targeted liposomal drug delivery.
Adv. Drug Deliv. Rev.
21
,
117
-133.

Arafat, T., Hentschel, P., Madajewicz, S., Manzione, J., Chowhan, N., Davis, R., Roche, P., Afif, I., Roque, C., Meek, A., and Magdy, S. (

1999
) Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors.
J. Neurooncol.
42
,
73
-77.

Bartus, R.T. (

1999
) The blood-brain barrier as a target for phamacological modulation.
Curr. Opin. Drug Discov. Dev.
2
,
152
-167.

Bickel, U., Yoshikawa, T., Landaw, E.M., Faull, K.F., and Pardridge, W.M. (

1993
) Pharmacologic effects in vivo in brain by vector-mediated peptide delivery.
Proc. Natl. Acad. Sci. U.S.A.
90
,
2618
-2622.

Bigner, D.D., Brown, M.T., Friedman, A.H., Coleman, R.E., Akabani, G., Friedman, H.S., Thorstad, W.L., McLendon, R.E., Bigner, S.H., Zhao, X.G., Pegram, C.N., Wikstrand, C.J., Herndon, J.E., II, Vick, N.A., Paleologos, N., Cokgor, I., Provenzale, J.M., and Zalutsky, M.R. (

1998
) Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results.
J. Clin. Oncol.
16
,
2202
-2212.

Black, K.L. (

1995
) Biochemical opening of the blood-brain barrier.
Adv. Drug Deliv. Rev.
15
,
37
-52.

Black, K.L., and Chio, C.C. (

1992
) Increased opening of blood tumour barrier by leukotriene C4 is dependent on size of molecules.
Neurol. Res.
14
,
402
-404.

Black, K.L., Cloughesy, T., Huang, S.-C., Gobin, Y.P., Zhou, Y., Grous, J., Nelson, G., Farahani, K., Hoh, C.K., and Phelps, M. (

1997
) Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas.
J. Neurosurg.
86
,
603
-609.

Blasberg, R.G. (

1977
) Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion.
Cancer Treat. Rep.
61
,
625
-631.

Blasberg, R.G., and Groothuis, D.R. (

1986
) Chemotherapy of brain tumors: Physiological and pharmacokinetic considerations.
Semin. Oncol.
13
,
70
-82.

Blasberg, R.G., Patlak, C.S., and Shapiro, W.R. (

1977
) Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration.
Cancer Treat. Rep.
61
,
633
-641.

Blasberg, R.G., Kobayashi, T., Horowitz, M., Rice, J., Groothuis, D.R., Molnar, P., and Fenstermacher, J.D. (

1983
) Regional blood-to-tissue transport in ethylnitrosourea-induced brain tumors.
Ann. Neurol.
14
,
202
-215.

Blasberg, R.G., Nakagawa, H., Bourdon, M.A., Groothuis, D.R., Patlak, C.S., and Bigner, D.D. (

1987
) Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: Kinetics and implications for diagnosis and therapy.
Cancer Res.
47
,
4432
-4443.

Boado, R.J., Tsukamoto, H., and Pardridge, W.M. (

1998
) Drug delivery of antisense molecules to the brain for the treatment of Alzheimer's disease and cerebral AIDS.
J. Pharm. Sci.
87
,
1308
-1315.

Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L., and Oldfield, E.H. (

1994
) Convection-enhanced delivery of macromolecules in the brain.
Proc. Natl. Acad. Sci. U.S.A.
91
,
2076
-2080.

Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Vick, N.A., Black, K., Sisti, M., Brem, S., Mohr, G., Muller, P., Morawetz, R., and Schold, S.C. (

1995
) Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas.
Lancet
345
,
1008
-1012.

Brown, M.T., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Reiman, R., Felsberg, G.J., Tien, R.D., Bigner, S.H., Zalutsky, M.R., Zhao, X.G., Wikstrand, C.J., Pegram, C.N., Herndon, J.E., II, Vick, N.A., Paleologos, N., Fredericks, R.K., Schold, S.C., Jr., and Bigner, D.D. (

1996
) Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results.
Clin. Cancer Res.
2
,
963
-972.

Burger, P.C. (

1987
) The anatomy of astrocytomas.
Mayo Clin. Proc.
62
,
527
-529.

Cao, X., and Shoichet, M.S. (

1999
) Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders.
Biomaterials
20
,
329
-339.

Chang, C.-M., and Bodmeier, R. (

1997
) Binding of drugs to monoglyceride-based drug delivery systems.
Int. J. Pharm.
147
,
135
-142.

Chang, H.-K., Gendelman, R., Lisziewicz, J., Gallo, R.C., and Ensoli, B. (

1994
) Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: A strategy for control of HIV-1.
Gene Ther.
1
,
208
-216.

Cowles, A.L., and Fenstermacher, J.D. (

1974
) Theoretical considerations in the chemotherapy of brain tumors. In Sartorelli, A.C., and Johns, D.G. (Eds.),
Handbook of Experimental Pharmacology
. Vol.
38
. Berlin: Springer Verlag. pp.
319
-329.

Cree, I.A., and Kurbacher, C.M. (

1997
) Individualizing chemotherapy for solid tumors: Is there any alternative?
Anticancer Drugs
8
,
541
-548.

de Lange, E.C.M., Danhof, M., de Boer, A.G., and Breimer, D.D. (

1997
) Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier.
Brain Res. Rev.
25
,
27
-49.

de Lange, E.C.M., de Boer, A.G, and Breimer, D.D. (

1999
) Microdialysis for pharmacokinetic analysis of drug transport to the brain.
Adv. Drug Deliv. Rev.
36
,
211
-227.

de Vries, H.E., Blom-Roosemalen, M.C.M., van Osten, M., de Boer, A.G., van Berkel, T.J.C., Breimer, D.D., and Kuiper, J. (

1996
) The influence of cytokines on the integrity of the blood-brain barrier
in vitro. J. Neuroimmunol.
64
,
37
-43.

Devineni, D., Klein-Szanto, A., and Gallo, J.M. (

1996
) In vivo microdialysis to characterize drug transport in brain tumors: Analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
Cancer Chemother. Pharmacol.
38
,
499
-507.

Donelli, M.G., Zucchetti, M., and D'Incalci, M. (

1992
) Do anticancer agents reach the tumor target in the human brain?
Cancer Chemother. Pharmacol.
30
,
251
-260.

Dropcho, E.J., Rosenfeld, S.S., Vitek, J., Guthrie, B.L., and Morawetz, R.B. (

1998
) Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas.
J. Neurooncol.
36
,
191
-198.

Dykstra, K.H., Hsiao, J.K., Morrison, P.F., Bungay, P.M., Mefford, I.N., Scully, M.M., and Dedrick, R.L. (

1992
) Quantitative examination of tissue concentration profiles associated with microdialysis.
J. Neurochem.
58
,
931
-940.

Eckman, W.W., Patlak, C.S., and Fenstermacher, J.D. (

1974
) A critical evaluation of the principles governing the advantages of intra-arterial infusions.
J. Pharmacokinet. Biopharm.
2
,
257
-285.

Emerich, D.F., Snodgrass, P., Pink, M., Bloom, F., and Bartus, R.T. (

1998
) Central analgesic actions of loperamide following the transient permeation of the blood brain barrier with Cereport (RMP-7).
Brain Res.
801
,
259
-266.

Ermisch, A., Brust, P., Kretzschmar, R., and Ruhle, H.-J. (

1993
) Peptides and blood-brain barrier transport.
Phys. Rev.
73
,
489
-527.

Farkkila, M., Jaaskelainen, J., Kallio, M., Blomstedt, G., Raininko, R., Virkkunen, P., Paetau, A., Sarelin, H., and Mantyla, M. (

1994
) Randomised, controlled study of intratumoral recombinantγ -interferon treatment in newly diagnosed glioblastoma.
Br. J. Cancer
70
,
138
-141.

Fenstermacher, J., and Gazendam, J. (

1981
) Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy.
Cancer Treat. Rep.
65
(Suppl. 2),
27
-37.

Fenstermacher, J.D., and Cowles, A.L. (

1977
) Theoretic limitations of intracarotid infusions in brain tumor chemotherapy.
Cancer Treat. Rep.
61
,
519
-526.

Ford, J., Osborn, C., Barton, T., and Bleehen, N.M. (

1998
) A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma.
Eur. J. Cancer
34
,
1807
-1811.

Friden, P.M., Walus, L.R., Watson, P., Doctrow, S.R., Kozarich, J.W., Backman, C., Bergman, H., Hoffer, B., Bloom F., and Granholm, A.-C. (

1993
) Blood-brain barrier penetration and in vivo activity of an NGF conjugate.
Science
259
,
373
-377.

Friden, P.M., Olson, T.S., Obar, R., Walus, L.R., and Putney, S.D. (

1996
) Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
J. Pharmacol. Exp. Ther.
278
,
1491
-1498.

Fung, L.K., Ewend, M.G., Sills, A., Sipos, E.P., Thompson, R., Watts, M., Colvin, O.M., Brem, H., and Saltzman, W.M. (

1998
) Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.
Cancer Res.
58
,
672
-684.

Ghersi-Egea, J.F., Finnegan, W., Chen, J.L., and Fenstermacher, J.D. (

1996
) Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat.
Neuroscience
75
,
1271
-1288.

Groothuis, D.R., and Levy, R.M. (

1997
) The entry of antiviral and antiretroviral drugs into the central nervous system.
J. Neurovirol.
3
,
387
-400.

Groothuis, D.R., Warkne, P.C., Molnar, P., Lapin, G.D., and Mikhael, M.A. (

1990
) Effect of hyperosmotic blood-brain barrier disruption on transcapillary transport in canine brain tumors.
J. Neurosurg.
72
,
441
-449.

Groothuis, D.R., Lippitz, B.E., Fekete, I., Schlageter, K.E., Molnar, P., Colvin, O.M., Roe, C.R., Bigner, D.D., and Friedman, H.S. (

1992
) The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.
Cancer Res.
52
,
5590
-5596.

Groothuis, D.R., Ward, S., Schlageter, K.E., Itskovich, A.C., Schwerin, S.C., Allen, C.V., Dills, C., and Levy, R.M. (

1998
) Changes in blood-brain barrier permeability associated with insertion of brain cannulas and microdialysis probes.
Brain Res.
803
,
218
-230.

Groothuis, D.R., Ward, S., Itskovich, A.C., Debrescu, C., Allen, C.V., Dills, C., and Levy, R.M. (

1999
) Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion.
J. Neurosurg.
90
,
321
-331.

Gundersen, S., Lote, K., and Watne, K. (

1998
) A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
Eur. J. Cancer
34
,
1565
-1569.

Gutman, M., Laufer, R., Eisenthal, A., Goldman, G., Ravid, A., Inbar, M., and Klausner, J.M. (

1996
) Increased microvascular permeability induced by prolonged interleukin-2 administration is attenuated by the oxygen-free-radical scavenger dimethylthiourea.
Cancer Immunol. Immunother.
43
,
240
-244.

Hendrikse, N.H., Schinkel, A.H., de Vries, E.G.E., Fluks, E., Van der Graaf, W.T.A., Willemsen, A.T.M., Vaalburg, W., and Franssen, E.J.F. (

1998
) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
Br. J. Pharmacol.
124
,
1413
-1418.

Hirano, Y., Mineura, K., Mizoi, K., and Tomura, N. (

1998
) Therapeutic results of intra-arterial chemotherapy in patients with malignant glioma.
Int. J. Oncol.
13
,
537
-542.

Hsiao, M., Tse, V., Carmel, J., Tsai, Y., Felgner, P.L., Haas, M., and Silverberg, G.D. (

1997
) Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogeneous wild-type p53 in vivo results in tumor suppression and long-term survival.
Biochem. Biophys. Res. Comm.
233
,
359
-364.

Inamura, T., and Black, K.L. (

1994
) Bradykinin selectively opens blood tumor barrier in experimental brain tumors.
J. Cereb. Blood Flow Metab.
14
,
862
-870.

Jain, R.K. (

1996
) Delivery of molecular medicine to solid tumors.
Science
271
,
1079
-1080.

Jain, R.K. (

1998
) The next frontier of molecular medicine: Delivery of therapeutics.
Nat. Med.
4
,
655
-657.

Kroll, R.A., and Neuwelt, E.A. (

1998
) Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means.
Neurosurgery
42
,
1083
-1100.

Laske, D.W., Morrison, P.F., Lieberman, D.M., Corthesy, M.E., Reynolds, J.C., Stewart-Henney, P.A., Koong, S.-S., Cummins, A., Paik, C.H., and Oldfield, E.H. (

1997a
) Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging.
J. Neurosurg.
87
,
586
-594.

Laske, D.W., Youle, R.J., and Oldfield, E.H. (

1997b
) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.
Nat. Med.
3
,
1362
-1368.

Leweke, F., Damian, M.S., Schindler, C., and Schachenmayr, W. (

1998
) Multidrug resistance in glioblastoma: Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
Pathol. Res. Pract.
194
,
149
-155.

Lieberman, D.M., Laske, D.W., Morrison, P.F., Bankiewicz K.S., and Oldfield, E.H. (

1995
) Convection enhanced distribution of large molecules in gray matter during interstitial drug infusion.
J. Neurosurg.
82
,
1021
-1029.

Menei, P., Venier-Julienne, M.C., and Benoit, J.P. (

1997
) Drug delivery into the brain using implantable polymeric systems.
STP Pharm. Sci.
7
,
53
-61.

Morgan, M.E., Singhal, D., and Anderson, B.D. (

1996
) Quantitative assessment of blood-brain barrier damage during microdialysis.
J. Pharmacol. Exp. Ther.
277
,
1167
-1176.

Morrison, P.F., Laske, D.W., Bobo, H., Oldfield, E.H., and Dedrick, R.L. (

1994
) High-flow microinfusion: Tissue penetration and pharmacodynamics.
Am. J. Physiol.
266
(1 Pt 2),
R292
-R305.

Nakagawa, H., Groothuis, D.R., and Blasberg, R.G. (

1984
) The effect of graded hypertonic intracarotid infusion on drug delivery to experimental RG-2 rat gliomas.
Neurology
34
,
1571
-1581.

Nakagawa, H., Groothuis, D.R., Owens, E.S., Fenstermacher, J.D., Patlak, C.S., and Blasberg, R.G. (

1987
) Dexamethasone effects on 125I-albumin distribution in experimental RG-2 gliomas and adjacent brain.
J. Cereb. Blood Flow Metab.
7
,
687
-701.

Nakashima, M., Shibata, S., Tokunaga, Y., Fujita, H., Anda, T., Arizono, K., Tomiyama, N., Sasaki, H., and Ichikawa, M. (

1997
) In vivo microdialysis study of the distribution of cisplatin into brain tumour tissue after intracarotid infusion in rats with 9L malignant glioma.
J. Pharm. Pharmacol.
49
,
777
-780.

Neuwelt, E.A., and Dahlborg, S.A. (

1989
) Blood-brain barrier disruption in the treatment of brain tumors: Clinical implications. In Neuwelt, E.A. (Ed.),
Implications of the Blood-Brain Barrier and Its Manipulation
. Vol.
2
. New York: Plenum Medical Book Co. pp.
195
-262.

Neuwelt, E.A., Frenkel, E.P., Diehl, J., Vu, L.H., and Hill, S. (

1980
) Reversible osmotic blood-brain barrier disruption in humans: Implications for the chemotherapy of malignant brain tumors.
Neurosurgery
7
,
44
-52.

Neuwelt, E.A., Balaban, E., Diehl, J., Hill, S., and Frenkel, E. (

1983
) Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood brain barrier opening.
Neurosurgery
12
,
662
-671.

Neuwelt, E.A., Barnett, P.A., and Frenkel, E.P. (

1984
) Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus induced brain tumors in the rodent: Observations on problems of drug delivery.
Neurosurgery
14
,
154
-160.

Normand-Sdiqui, N., and Akhtar, S. (

1998
) Oligonucleotide delivery: Uptake of rat transferrin receptor antibody (OX-26) conjugates into an in vitro immortalised cell line model of the blood-brain barrier.
Int. J. Pharm.
163
,
63
-71.

Olivi, A., and Brem, H. (

1994
) Interstitial chemotherapy with sustained release polymer systems for the treatment of malignant gliomas.
Recent Results Cancer Res.
135
,
149
-154.

Ostrowitzki, S., Fick, J., Roberts, T.P.L., Wendlend, M.F., Aldape, K.D., Mann, J.S., Israel, M.A., and Brasch, R.C. (

1998
) Comparison of gadopentetate dimeglumine and albumin-(Gd-DTPA)30 for microvessel characterization in an intracranial glioma model.
J. Magn. Reson. Imaging
8
,
799
-806.

Pardridge, W.M. (

1995
) Vector-mediated peptide delivery to the brain.
Adv. Drug Deliv. Rev.
15
,
109
-146.

Pardridge, W.M. (

1997
) Drug delivery to the brain.
J. Cereb. Blood Flow Metab.
17
,
713
-731.

Pardridge, W.M. (

1998
) CNS drug design based on principles of blood-brain barrier transport.
J. Neurochem.
70
,
1781
-1792.

Pardridge, W.M., Kang, Y.-S., Buciak, J.L., and Yang, J. (

1995
) Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate.
Pharm. Res.
12
,
807
-816.

Parker, J.C., Perry, M.A., and Taylor, A.E. (

1984
) Permeability of the microvascular barrier. In Staub, N.C., and Taylor, A.E. (Eds.),
Edema
. New York: Raven Press. pp.
143
-188.

Parsons, L.H., and Justice, J.B., Jr. (

1994
) Quantitative approaches to in vivo brain microdialysis.
Crit. Rev. Neurobiol.
8
,
189
-220.

Patlak, C.S., and Fenstermacher, J.D. (

1975
) Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion.
Am. J. Physiol.
229
,
877
-884.

Puri, R.K., Hoon, D.S., Leland, P., Snow, P., Rand, R.W., Pastan, I., and Kreitman, R.J. (

1996
) Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant glioma.
Cancer Res.
56
,
5631
-5637.

Ram, Z., Culver, K.W., Oshiro, E.M., Viola, J.J., DeVroom, H.L., Otto, E., Long, Z., Chiang, Y., McGarrity, G.J., Muul, L.M., Katz, D., Blaese, R.M., and Oldfield, E.H. (

1997
) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.
Nat. Med.
3
,
1354
-1361.

Rapoport, S.I. (

1996
) Modulation of blood-brain barrier permeability.
J. Drug Target
.
3
,
417
-425.

Rapoport, S.J., and Thompson, H.K. (

1973
) Osmotic opening of the blood-brain barrier in the monkey without associated neurological deficits.
Science
180
,
971
.

Rubertone, J.A., Woo, D.V., Emrich, J.G., and Brady, L.W. (

1993
) Brain uptake of thallium-201 from the cerebrospinal fluid compartment.
J. Nucl. Med.
34
,
99
-103.

Sakamoto, A., and Ido, T. (

1993
) Liposome targeting to rat brain: Effect of osmotic opening of the blood-brain barrier.
Brain Res.
629
,
171
-175.

Sanovick, E., Bartus, R.T., Friden, P.M., Dean, R.L., Le, H.Q., and Brightman, M.W. (

1995
) Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7.
Brain Res.
705
,
125
-135.

Schinkel, A.H. (

1999
) P-glycoprotein, a gatekeeper in the blood-brain barrier.
Adv. Drug Deliv. Rev.
36
,
179
-194.

Schlageter, K.E., Molnar, P., Lapin, G.D., and Groothuis, D.R. (

1999
) Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties.
Microvasc. Res.
58
,
312
-328.

Schroeder, U., Sommerfeld, P., Ulrich, S., and Sabel, B.A. (

1998
) Nanoparticle technology for delivery of drugs across the blood-brain barrier.
J. Pharm. Sci.
87
,
1305
-1307.

Sherman, M.E., Erozan, Y.S., Mann, R.B., Kumar, A.A.J., McArthur, J.C., Royal, W., Uematsu, S., and Nauta, H.J.W. (

1991
) Stereotactic brain biopsy in the diagnosis of malignant lymphoma.
Am. J. Clin. Pathol.
95
,
878
-883.

Song, C.X., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W.R., Shebuski, R.J., and Levy, R.J. (

1997
) Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery.
J. Controlled Release
43
,
197
-212.

Stewart, D.J. (

1994
) A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.
J. Neurooncol.
20
,
121
-139.

Tamai, I., and Tsuji, A. (

1996
) Drug delivery through the blood-brain barrier.
Adv. Drug Deliv. Rev.
19
,
401
-424.

Tamai, I., Sai, Y., Kobayashi, H., Kamata, M., Wakamiya, T., and Tsuji, A. (

1997
) Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier.
J. Pharmacol. Exp. Ther.
280
,
410
-415.

Taylor, A.E., and Granger, D.N. (

1984
) Exchange of macromolecules across the microcirculation. In Renkin, E.M., and Michel, C.C. (Eds.),
Handbook of Physiology
. Sect. 2, Vol.
IV
, Part 1. Bethesda, Md.: American Physiological Society. pp.
467
-520.

Tomita, T. (

1991
) Interstitial chemotherapy for brain tumors: Review.
J. Neurooncol.
10
,
57
-74.

Tsuji, A., and Tamai, I. (

1997
) Blood-brain barrier function of P-glycoprotein.
Adv. Drug Deliv. Rev.
25
,
287
-298.

van de Waterbeemd, H., Camenish, G., Folkers, G., Chretien, J.R., and Raevsky, O.A. (

1998
) Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors.
J. Drug Target
.
6
,
151
-165.

Vick, N.A., Khandekar, J.D., and Bigner, D.D. (

1977
) Chemotherapy of brain tumors: The “blood-brain barrier” is not a factor.
Arch. Neurol.
34
,
523
-526.

Viola, J.J., Agbaria, R., Walbridge, S., Oshiro, E.M., Johns, D.G., Kelley, J.A., Oldfield, E.H., and Ram, Z. (

1995
) In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors.
Cancer Res.
55
,
1306
-1309.

von Bossanyi, P., Diete, S., Dietzmann, K., Warich-Kirches, M., and Kirches, E. (

1997
) Immunohistochemical expression of P-glyoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy.
Acta Neuropathol.
94
,
605
-611.

Westergren, I., Nystrom, B., Hamberger, A., and Johansson, B.B. (

1995
) Intracerebral dialysis and the blood brain barrier.
J. Neurochem.
64
,
229
-234.

Yang, W., Barth, R.F., Adams, D.M., and Soloway, A.H. (

1997
) Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors.
Cancer Res.
57
,
4333
-4339.

Yoshikawa, T., Sakaeda, T., Sugawara, T., Hirano, K., and Stella, V.J. (

1999
) A novel chemical delivery system for brain targeting.
Adv. Drug Deliv. Rev.
36
,
255
-275.

Zunkeler, B., Carson, R.E., Olson, J., Blasberg, R.G., DeVroom, H., Lutz, R.J., Saris, S.C., Wright, D.C., Kammerer, W., Patronas, N.J., Dedrick, R.L., Herscovitch, P., and Oldfield, E.H. (

1996
) Quantification and pharmacokinetics of blood-brain barrier disruption in humans.
J. Neurosurg.
85
,
1056
-1065.

PDF
This content is only available as a PDF.
© 2000 by the Society for Neuro-Oncology
Topic:
Issue Section:
Review Article
Download all slides